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INTRODUCTION
Stroke is a major cause of death and disability in adults 
worldwide. Although the etiology of stroke may be ischemia 
or hemorrhage, ischemic stroke accounts for about 80% of all 
stroke cases (Chalela et al., 2004). The only approved therapy 
for ischemic stroke is fibrinolysis with recombinant tissue plas-
minogen activator (rtPA). However, rtPA can be administered 
in a limited number of cases because of its short therapeutic 
window. Therefore, additional strategies are required to man-
age ischemic stroke.
Inflammation is a major part of the pathophysiology of stroke 
(Amantea et al., 2009) and interleukin (IL)-1 is an essen tial 
mediator of cerebral ischemia injury (Allan et al., 2005; Simi 
et al., 2007). The IL-1 receptor antagonist (IL-1RA) is a com-
petitive IL-1 antagonist and induced by the same stressors 
as IL-1, which can block all types of IL-1 action (Hannum et 
al., 1990). In animal experiments, IL-1RA administration can 
considerably decrease cerebral ischemia injury, even when 
administered peripherally to comorbid animals after the on-
set of ischemia (Loddick and Rothwell, 1996; Mulcahy et al., 
2003; Pradillo et al., 2012). However, in a clinical trial, IL-1RA 
administration did not directly improve clinical outcomes such 
as infarct volume and survival rate in acute stroke patients 
(Emsley et al., 2005). One of the reasons why IL-1RA failed 
to demonstrate efficacy in the clinical situation may be the in-
adequate delivery of IL-1RA to the central nervous system. A 
meta-analysis of the efficacy of IL-1RA in animal models of 
stroke supports this assumption by demonstrating that greater 
neuroprotection could be achieved with central administration 
than with peripheral administration of IL-1RA (Banwell et al., 
2009). Therefore, a more efficient route of delivery of IL-1RA 
to brain parenchyma is required.
The blood-brain barrier (BBB) is known to be a major bar-
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rier against the delivery of pharmacologically relevant quanti-
ties of therapeutic proteins to the brain. IL-1RA is a large (17 
kDa) hydrophilic peptide. Thus, the penetration of peripherally 
administered IL-1RA into the brain was reported to be limited 
(Gutierrez et al., 1994). On the other hand, intranasal admin-
istration has been emerging as the effective delivery route of 
therapeutic proteins to the brain by bypassing the BBB (Maler-
ba et al., 2011). However, a study on intranasal administration 
of IL-1RA to protect the brain against stroke has hardly ever 
been undertaken. This study was designed to compare be-
tween intranasal and systemic administrations of IL-1RA from 
the viewpoints of efficiency of brain penetration and neuro-
protection.
MATERIALS AND METHODS
Animals
This experiment protocol was approved by the Yonsei Uni-
versity Animal Care and Use Committee (protocol number: 
2012-0235; Seoul, Korea) and was in accordance with the 
National Institutes of Health guidelines for the care and use 
of laboratory animals. Male Sprague-Dawley rats aged 8-10 
weeks, weighing 280-320 g, were obtained from Orientbio Inc. 
(Seongnam, Korea) and used for this study. The rats were 
maintained under a 12-h light-dark cycle and allowed free ac-
cess to food and water before and after surgery.
Transient focal cerebral ischemia
Focal cerebral ischemia was induced by transient occlusion 
of the middle cerebral artery (MCA). The experimental MCA 
occlusion (MCAO) was performed as previously described 
(Belayev et al., 1996). Anesthesia was induced with intraperi-
toneal injection of a mixture of 30 mg/kg zoletil (Virbac Labo-
ratory, Carros, France) and 10 mg/kg xylazine (Bayer Korea 
Ltd., Seoul, Korea). Zoletil is a combination of a dissociative 
anesthetic, tiletamine hydrochloride, and a benzodiazepine, 
zolazepam hydrochloride. Tiletamine is a non-competitive an-
tagonist at the phencyclidine site of the N-methyl-D-aspartate 
receptor. Xylazine is an alpha-2 adrenergic agonist that ex-
erts effects on presynaptic and postsynaptic receptors of the 
central and peripheral nervous systems. The rats were placed 
in the supine position on a heated pad, with their body tem-
peratures maintained at 37°C ± 0.5°C according to a rectal 
thermometer. Under an operating microscope, the right com-
mon carotid, external carotid (EC), and internal carotid (IC) 
arteries were exposed through a midline incision. The EC ar-
tery was ligated, coagulated, and cut down just proximal to the 
lingual and maxillary artery branches. All the other branches of 
the EC artery were coagulated and transected. The IC artery 
was then isolated from the vagus nerve to prevent damage. 
A 4-0 monofilament nylon suture (Dermalone, United States 
Surgical, CT, USA) with a flame-rounded head was inserted 
through the IC artery via a small incision in the EC artery 
stump. The distance from bifurcation of the common carotid 
artery to the tip of the suture was approximately 18.5 mm in 
all the rats, which is consistent with published descriptions of 
the MCAO model. Cerebral blood flow was monitored by us-
ing laser Doppler flowmetry (Omega flow, FLO-C1, Neurosci-
ence, Tokyo, Japan) with a flexible probe placed in the cortical 
areas supplied by the MCA (2 mm posterior and 6 mm lateral 
to the bregma). When the MCA was occluded by thread inser-
tion, rats that did not show a cerebral blood flow reduction of 
at least 70% were excluded from the experiment (Xing et al., 
2008). After 60 min of occlusion, the suture was withdrawn, 
the skin was sutured, and the rats were allowed to recover.
Treatments
The rats were randomly divided into 3 groups. All of the rats 
underwent MCAO/reperfusion as described earlier. The IN 
group intranasally received 50 mg/kg human IL-1RA (Kineret, 
Amgen Manufacturing, Ltd., Thousand Oaks, CA, USA). Intra-
nasal administration of 0.5 mL/kg Kineret (undiluted solution, 
approximately 100 μL) was performed in 8- to 10-μL drops by 
using a pipette, treating each nare every 5 min for 60 min from 
the start of MCAO. In addition, 0.5 mL/kg 0.9% saline was 
administered intraperitoneally at the start of MCAO. The IP 
group received 50 mg/kg IL-1RA intraperitoneally at the start 
of MCAO and the same volume of 0.9% saline intranasally in 
the same manner as did the IN group. The EC group received 
0.5 mL/kg 0.9% saline through both the intranasal and intra-
peritoneal routes. 
The administration dose of human IL-1RA was determined 
based on previous studies. The systemic administration of 
100 mg/kg human IL-1RA showed neuroprotective effects in 
rat models of cerebral ischemia when given at the beginning 
of ischemia (Garcia et al., 1995a; Relton et al., 1996; Green-
halgh et al., 2010). We used half of this dose (50 mg/kg) in the 
present study to investigate whether the neuroprotective prop-
erties of IL-1RA could also be guaranteed at a lower dose. 
In order to compare the amount of IL-1RA reaching the brain 
parenchyma according to route of administration, the same 
dose was used for intranasal administration. 
Neurobehavioral assessment
Neurological deficits were assessed before and 1, 2, 4, and 
7 days after MCAO. Two examiners who were blinded to the 
treatment conditions consecutively and independently per-
formed the neurological examinations of the animals. Adher-
ence to a predetermined time excluded behavioral changes 
based on the circadian rhythm. The neurological examination 
consisted of 6 tests developed and described by Garcia et al. 
(1995b). The score assigned to each rat at the completion of 
the evaluation equaled the sum of all the scores in the follow-
ing 6 tests: (1) spontaneous activity; (2) symmetry in move-
ment of the 4 limbs; (3) forepaw outstretching; (4) climbing; (5) 
body proprioception; and (6) response to vibrissae touch. The 
final maximum neurological score was 18.
The rota-rod test was used to assess the recovery of im-
paired motor function after MCAO. This accelerating rota-rod 
test (ENV-577, Med Associates Inc., Georgia, VT, USA) was 
conducted as described by Hunter et al. (2000). The exercise 
time, which is the time the animals remained on an acceler-
ating rota-rod cylinder, was measured. Speed was increased 
from 4 to 40 rpm within 5 min. The trial ended if the animal fell 
off the rungs or gripped the device and spun around for 2 con-
secutive revolutions without attempting to walk on the rungs. 
The exercise time on the rota-rod was measured for each rat 
5 times per day before and 1, 2, 4, and 7 days after MCAO.
Infarct volume
On the seventh day after MCAO, the animals were anes-
thetized and decapitated. The brains were quickly isolated 
and sectioned into 2-mm-thick serial coronal slices. The brain 
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slices were stained with 2% 2,3,5-triphenyltetrazolium chloride 
(TTC; Sigma Aldrich, St Louis, MO, USA) in the dark at 37°C 
for 30 min and fixed with 4% paraformaldehyde (PFA, Sigma 
Aldrich) overnight. The posterior surface of each slice was 
photographed and analyzed by using a computer-assisted im-
age analysis system (Optimas ver 6.1, Optimas, Bothell, WA, 
USA). The lesion volume was calculated by multiplying the 
area by the thickness of the slices. We adopted a previously 
described method to eliminate the contribution of edema to 
the ischemic lesion and to correct for the individual difference 
in brain volumes by using the percentage of infarct volume 
in the ipsilateral hemisphere volume (Belayev et al., 1996). 
Edema volume was calculated by subtracting the volume of 
the contralateral hemisphere from that of the ipsilateral hemi-
sphere. The percentage of edema volume was calculated as 
(edema volume/contralateral hemisphere volume).
Determination of the administered human IL-1RA level 
(enzyme-linked immunosorbent assay)
Serum and brain tissues, including the striatum and cor-
tex, were obtained during appointment and were stored in 
aliquots at -80°C until use for different assays. Serum levels 
of human IL-1RA were measured by using high-sensitivity 
enzyme-linked immunosorbent assay (ELISA) kits (Quanti-
kine ELISA, R&D Systems, Minneapolis, MN, USA) accord-
ing to the manufacturer’s instructions. To measure the human 
IL-1RA level in brain tissue, total proteins of brain tissues, 
including the striatum and cortex, were extracted by using a 
tissue protein extraction reagent (T-PER Tissue Protein Ex-
traction Reagent, Thermo Scientific, Waltham, MA, USA). In 
brief, the weight of the striatal and cortical tissues was mea-
sured, and the reagent was added (20-μL reagent per 1-mg 
tissue). Inhibitor cocktail (100X Halt protease and phosphate 
inhibitor cocktail, Thermo 1861281, Thermo Scientific) were 
also added to the reagent for protection of intact active cellular 
proteins from degradation, and the striatal and cortical tissues 
were then homogenized. After centrifugation, the supernatant 
was collected. Protein concentration was determined by using 
the BCA Protein Assay Kit (Thermo Scientific) according to 
the manufacturer’s methods. To calculate the protein yield in 
a maximum of 20,000 pg/mL, we measured the sample area 
by using the manufacturer’s instruction standard. The human 
IL-1RA levels in brain tissue lysate were assayed in high sen-
sitivity ELISA kits (Quantikine ELISA, R&D Systems) accord-
ing to the manufacturer’s instructions. Samples were added at 
100 μL per plate and incubated for 2 h at room temperature. 
After washing with a wash buffer, 200 μL of human IL-1RA 
conjugates was added to each sample and incubated for 2 h. 
After reaction, the wavelength was read at 450 nm by using a 
microplate reader.
Assessment of proinflammatory cytokine expression 
(reverse transcriptase polymerase chain reaction)
Total RNA was prepared from the cortex of the ipsilateral 
hemisphere by using an RNeasy Mini Kit (Qiagen, Austin, 
Texas, USA) according to the manufacturer’s directions. Brief-
ly, recommended amounts of tissue (25 mg) were placed in 
the appropriate lysis buffer supplied with the kit (add 10 μL of 
β-mercaptoethanol to 1 mL of lysis buffer). At this point, the 
manufacturer’s protocol was followed. The RNA was eluted 
with 30-50 μL of RNase-free H2O. The samples were imme-
diately aliquoted and stored at -80°C. RNA was quantified by 
measuring A260 absorbance in NanoDrop ND-1000 (Thermo 
Scientific). Purity was assessed by calculating the A260/A280 
ratio. cDNA was synthesized with 1 μg of total RNA from each 
sample by using a Maxime Reverse Transcriptase (RT) PreMix 
kit (OligodT Primer, iNtRON Biotechnology, Inc., Seongnam, 
Korea). The diluted cDNA was amplified with SYBR Green 
Polymerase Chain Reaction (PCR) Master Mix (Applied Bio-
systems, Foster City, CA, USA) in a final volume of 50 μL. The 
PCR was performed by using an ABI prism 7500 sequence 
detector (Applied Biosystems). The PCR program consisted of 
initial denaturation at 95°C for 10 s and 40 cycles at 95°C for 5 
s, 60°C for 34 s, 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s. 
The primers for b-actin (forward, 5’-GGCATCCTGACCCTGA-
AGTA-3’ and reverse, 5’-GGGGTGTTGAAGGTCTCAAA-3’), 
IL-1β (forward, 5’-CACCTCTCAAGCAGAGCACAG-3’ and re- 
verse,  5’-GGGTTCCATGGTGAAGTCAAC-3’),  TNF-α  (forward, 
5’-CAGGAGAAAGTCAGCCTCCT-3’ and reverse, 5’-TCATA- 
CCAGGGCTTGAGCTCA-3’), and IL-6 (forward, 5’-CGAAAGT-
CAACTCCATCTGCC-3’ and reverse, 5’-GGCAACTGGCTG-
GAAGTCTCT-3’) were purchased from Bioneer Inc (Seong-
nam, Korea). The cycling threshold (Ct) values of IL-1β, IL-6, 
and TNF-α were normalized to Ct values of b-actin. All the 
samples were run in triplicate, and the animals that underwent 
sham surgery without MCAO served as controls.
Immunohistochemistry
Brain tissue samples were obtained at 6 h after MCAO 
and fixed in 3.7% formaldehyde in phosphate-buffered saline 
(PBS). After fixation, the isolated brain tissues were soaked in 
30% sucrose at 4°C overnight. For cryosection, the samples 
were embedded in optimum cutting temperature compound 
(Tissue-Tek, Sakura, Japan) and frozen at -80°C. The brain tis-
sues were sectioned coronally at a 20-μm thickness by using 
a cryotome (Leica Instruments GmbH, Nussloch, Germany) 
and placed on Muto silane-coated microscope slides (Muto 
Pure Chemicals, Tokyo, Japan). For immunohistochemistry of 
NeuN, Iba-1, IL-1β, and IL-1ra, the slides were defrosted and 
immersed in 0.3% Triton X-100 for 1 h for antigen retrieval and 
washed with PBS 3 times for 5 min. Then, the samples were 
incubated with EtOH at -20°C for 10 min and dried for 30 sec. 
Bovine serum albumin (BSA) solution (5%) was used for the 
blocking process. Tissue sections were incubated overnight at 
4°C with primary antibodies, diluted in 2% BSA with PBS such 
as monoclonal mouse anti-NeuN (1:50; Millipore, Bedford, 
MA, USA), monoclonal mouse anti-Iba-1 (1:50; Abcam, Cam-
bridge, UK), polyclonal rabbit anti-IL-1β (1:50, Abcam), and 
polyclonal goat anti-IL-1ra (R&D Systems). The next day, fluo-
rescein isothiocyanate-conjugated anti-mouse IgG (1:5,000; 
Millipore), rhodamine-conjugated anti-goat IgG (1:5,000; Mi-
llipore), rhodamine-conjugated anti-rabbit IgG antibodies (1: 
5,000; Millipore) were incubated at room temperature for 1 h 
as secondary antibodies. The slides were washed with PBS. 
4’6-Diamidino-2-phenylindole was used for counterstaining, 
and slides were covered with VECTASHIELD mounting me-
dium (Vecta Laboratories, CA, USA). The tissue sections were 
observed under an LSM700 confocal laser scanning micro-
scope (Carl Zeiss, Thornwood, NY, USA).
 Statistical analysis
All data were presented as mean (standard error of the 
mean [SEM]). The 2 groups were compared by performing 
an independent 2-tailed t test. One-way analysis of variance 
152https://doi.org/10.4062/biomolther.2016.050
with Bonferroni post hoc tests was used for comparisons be-
tween the 3 groups. Serial data from neurobehavioral tests 
were compared by using repeated-measures analysis of vari-
ance with Bonferroni correction. Statistical analyses were 
performed with IBM SPSS Statistics 20 (IBM Software Group, 
Chicago, IL, USA). A p-value of <0.05 was considered statisti-
cally significant.
RESULTS
Neurobehavioral function and infarct size
In order to evaluate the effects of intranasal IL-1RA on the 
neurological outcome of transient focal cerebral ischemia, 
neurobehavioral function, infarct, and edema volume were as-
sessed. Two rats in the EC group and one in the IP group died 
before the completion of the assessments. The comparisons 
for infarct and edema size were performed by using one-way 
analysis of variance with the Bonferroni post hoc test (Fig. 1). 
On the seventh day after MCAO, the IN group had significantly 
lesser infarct volume than the EC group (p=0.001). However, 
the difference in infarct volume between the IN and IP groups 
did not reach statistical significance (p=0.087), and neither did 
the difference between the EC and IP groups (p=0.099; Fig. 
1B). In addition, a similar pattern was observed in the differ-
ence in edema volume between the 3 groups (p=0.002 for the 
IN group vs. the EC group; p=0.154 for the IN group vs. the IP 
group; and p=0.382 for the IP group vs. EC group) as shown 
in Fig. 1C.
The neurological score before MCAO was 18 in all the 
experimental rats because no neurological deficit was pres-
ent. By the seventh day after MCAO, the IN group showed 
significantly greater neurological scores than the EC and IP 
groups (p<0.001 by repeated-measures analysis of variance). 
No significant difference in neurological score was observed 
between the IP and EC groups during the period (Fig. 2A). In 
the rota-rod test, no statistically significant difference in the 
change in the exercise duration after MCAO was observed be-
tween the 3 groups (p=0.064 by repeated-measures analysis 
of variance). However, the mean exercise durations in the IN 
group on days 4 and 7 after MCAO were greater than those 
in other groups, although the differences were not statistically 
significant (Fig. 2B).
Administered human IL-1RA concentration in brain  
parenchyma and serum
Human IL-1RA concentrations in brain parenchyma, includ-
ing the cortex and striatum, and serum were measured at 1, 3, 
6, and 24 h after MCAO. Fig. 3 shows the human IL-1RA con-
centrations in serum and brain tissue. After intranasal admin-
istration, human IL-1RA already reached significant concen-
trations in both of the striatum and cortex at the first sampling 
time (1 h after MCAO; Fig. 3A, 3B). In the striatum, the IL-1RA 
concentration at 1 h after MCAO was highest (11,265 ± 2,105 
pg/mL) among the measurement time points. On the other 
hand, the IL-1RA concentration in the cortex was the highest 
at 3 h after MCAO (10,130 ± 750 pg/mL). After intraperitoneal 
administration, the IL-1RA concentration was highest at 3 h af-
ter MCAO in both the striatum (2,369 ± 1,097 pg/mL) and cor-
tex (3,682 ± 1,863 pg/mL). In the all measurement time points, 
the IL-1RA concentrations were significantly greater in the IN 
group than in the IP group (by independent 2-tailed t test).
Fig. 3C depicts the serum levels of human IL-1RA. The IL-
1RA levels at 1 h after MCAO were highest in both groups 
(IN group: 222,274 ± 47,209 pg/mL [222 ng/mL]; IP group: 
31,661,574 ± 2,403,415 pg/mL [31,662 ng/mL]). At all the 
measurement time points, the serum concentrations of IL-1RA 
were significantly higher in the IP group than in the IN group 
(by independent 2-tailed t test). Especially the IP group had 
more than 142 times greater IL-1RA serum concentration than 
the IN group at 1 h after MCAO.
According to the manufacturer, the anti-human IL-1RA anti-
body used in the ELISA in this study shows no cross-reactivity 
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Fig. 1. Neuroprotective effects of intranasal IL-1RA against tran-
sient cerebral ischemia. Brain damage is assessed by using TTC 
staining 7 days after the ischemic insult (cerebral ischemia for 1 h). 
The EC, IN, and IP groups received vehicle, intranasal IL-RA, and 
intraperitoneal IL-1RA, respectively. Representative TTC staining 
images of brain sections for each group (A). Quantitative compari-
sons of infarct volume (B) and edema volume (C) (n=5 in the EC 
group, n=7 in the IN group, and n=6 in the IP group). Values are 
shown as mean (SEM). *p<0.005, versus the EC group by one-
way analysis of variance with Bonferroni post hoc test.
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with rat IL-1RA. We also confirmed that IL-1RA was not de-
tected in the EC group over all the measurement time points.
Distribution of the administered human IL-1RA and IL-1β
Cellular distribution of intranasal IL-1RA was assessed by 
using immunohistochemistry 6 h after MCAO. Fig. 4 shows the 
immunoreactivity of IL-1RA, which coincides with the NeuN 
(Fig. 4B) and Iba1 staining (Fig. 4C) in the ipsilateral striatum 
and cortex. The EC group rarely had IL-1RA staining in both 
the striatum and cortex. On the other hand, the IN group dem-
onstrated strong immunoreactivity of IL-RA, which was largely 
colocalized with NeuN (Fig. 4A) and Iba-1 (Fig. 4B). According 
to the manufacturer of the anti-human IL-1RA antibody used in 
the immunohistochemistry, cross-reactivity with rat IL-1RA has 
not been reported yet (only less than 15% cross-reactivity with 
mouse was described). However, minimal immunoreactivity 
was observed in the EC group.
Fig. 5 exhibits the IL-1β expression 6 h after MCAO in the 
cortex and striatum. The EC group had greater IL-1β immuno-
reactivity, which was colocalized with NeuN (Fig. 5A) and Iba1 
(Fig. 5B) when compared with the IN group, which imposed 
that intranasal IL-1RA suppressed the IL-1β expression.
Inflammatory cytokine expression after intranasal admin-
istration of IL-1RA
The effects of intranasal IL-1RA on the mRNA levels of IL-
1β and TNF-α after transient focal cerebral ischemia were 
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Fig. 2. Neurobehavioral function evaluation after transient cere-
bral ischemia and IL-1RA administration. Neurobehavioral function 
is assessed by using an 18-point neurological scoring system (A) 
and a rota-rod test (B) (n=5 in EC group, n=7 in IN group, and n=6 
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MCAO between the 3 groups did not have any statistical signifi-
cance. Values are shown as mean (SEM). *p<0.01, versus the EC 
and IP groups at each time point by one-way analysis of variance 
with Bonferroni post hoc test.
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Fig. 3. Level of human IL-1RA in the ipsilateral hemisphere (stria-
tum [A] and cortex [B]) and the serum (C) from the rats with tran-
sient cerebral ischemia after intranasal (■) or intraperitoneal (□) 
administration of human IL-1RA (50 mg/kg). Human IL-1RA was 
not detected in the EC group over all the measurement time points. 
Values are shown as mean concentration (SEM). In each group, 5 
rats were assessed at each measurement time point. *p<0.05, ver-
sus the IP group at each time point by independent 2-tailed t test.
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Fig. 5. The effect of intranasal IL-1RA administration on IL-1β expression. In the EC group, IL-1β is detected with strong immunoreactivity 
and largely co-localized with NeuN (A) and Iba-1(B) in the striatum and cortex. However, the IL-1β expression level is remarkably reduced 
at 6 h after intranasal administration of IL-1RA in the IN group.
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evaluated by using semiquantitative RT-PCR. The values 
were expressed as a ratio in comparison with the sham con-
trol. As shown in Fig. 6, the IN group had significantly lower 
mRNA levels of IL-1β and TNF-α than the EC group at 6 h 
after MCAO (by independent 2-tailed t test).
DISCUSSION
The present study demonstrated that intranasal delivery 
of IL-1RA significantly reduced the size of infarct lesion and 
alleviated neurological impairment by 7 days after transient 
focal cerebral ischemia. However, systemic administration 
of IL-1RA neither significantly decreased the infarct size nor 
improved neurological impairment. The administered human 
IL-1RA concentrations of brain tissue were significantly high-
er in the intranasal than in the systemic administration at all 
measurement points for 24 h after cerebral ischemia. On the 
other hand, in the serum, the administered IL-1RA was de-
tected significantly less in the intranasal than in the systemic 
administration at every measurement time point. Finally, our 
results showed that the intranasally administered IL-1RA was 
deposited in neurons and activated microglia, and suppressed 
inflammatory cytokines after cerebral ischemia. Therefore, the 
superior neuroprotective efficacy of intranasal administration 
to systemic administration may have resulted from the greater 
delivery of IL-1RA into brain tissues, which can suppress neu-
roinflammation after transient focal cerebral ischemia.
Previous experimental studies already demonstrated the 
efficacy of IL-1RA in cerebral ischemia model 2 decades ago 
(Martin et al., 1994; Garcia et al., 1995a; Relton et al., 1996). 
Furthermore, in a recent investigation, IL-1RA administration 
was reported to reduce neuroinflammation and ischemic brain 
injury in aged and obese rats (Pradillo et al., 2012), elevat-
ing IL-1RA closer to the standards for preclinical neuroprotec-
tive and restorative drug development (Fisher et al., 2009). 
In addition, systemic administration of IL-1RA at a clinically 
safe dose to patients with subarachnoid hemorrhage (SAH) 
maintained the IL-1RA concentration in the cerebrospinal fluid 
(CSF) at which IL-1RA was reported to provide neuroprotec-
tion against transient cerebral ischemia in rats (Clark et al., 
2008). In spite of these experimental backgrounds, the phase 
II clinical trial of IL-1RA in acute stroke patients failed to prove 
efficacy (Emsley et al., 2005). According to pharmacokinetic 
data of IL-1RA in rats, the CSF concentration of IL-1RA was 
only 2-5.1% of the plasma concentration after transient ce-
rebral ischemia (Clark et al., 2008; Greenhalgh et al., 2010). 
The human data of the patients with SAH demonstrated that 
the CSF concentration of IL-1RA was also only 4% of that in 
plasma at best (Gueorguieva et al., 2008). Furthermore, the 
penetration of IL-1RA into brain tissue only appeared in the le-
sion with BBB breakdown when the rats received systemic ad-
ministration of IL-1RA, and the CSF concentration of IL-1RA 
may not reflect the level of brain parenchyma (Greenhalgh et 
al., 2010). Therefore, one of the possible causes of failure in 
the clinical trial of IL-1RA may be the insufficient delivery of 
IL-1RA to the brain tissue (Banwell et al., 2009). Thus, the 
efficiency of the delivery should be improved and the delivery 
to the brain parenchyma, not in the CSF, should be assessed. 
This investigation assessed and compared the delivery of IL-
1RA to the brain according to the administration pathway by 
measuring the IL-1RA concentrations in the brain tissue.
Until recently, the intranasal administration of various thera-
peutic proteins has been investigated not only in stroke mod-
els (Fletcher et al., 2009; Sun et al., 2016) but also in other 
neurological disease models (Malerba et al., 2011). Drugs that 
are administered through the nasal route may be absorbed 
into the systemic circulation across the nasal membrane or 
transported directly to the brain tissue along the olfactory and 
trigeminal nerves (Dhuria et al., 2010). Although it is possible 
that after intranasal administration, the drug is absorbed into 
the systemic circulation and subsequently transported into 
the brain across the BBB, large and hydrophilic therapeutics 
such as IL-1RA cannot easily enter the blood circulation, as 
revealed by our results. When the same IL-1RA dose was 
given through the intraperitoneal or intranasal route, the peak 
serum concentration of IL-1RA in the IN group was only about 
0.7% of that in the IP group, although the IL-1RA level in the 
brain tissue was significantly higher in the IN group than in 
the IP group. Direct delivery to the brain after intranasal ad-
ministration is supposed to involve 2 mechanisms (Dhuria et 
al., 2010). One is an extracellular pathway in which the drug 
is rapidly transported to the olfactory bulb or brain stem along 
the olfactory or trigeminal nerve through intercellular clefts. 
The other is by endocytosis of the drug into olfactory sensory 
neurons and intracellular transport along axons to the olfac-
tory bulb, which is known to be a much slower process. Our 
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Fig. 6. Time course of inflammatory cytokine expressions in the 
ischemic hemisphere after transient cerebral ischemia. Quantita-
tive mRNA expressions of IL-1β and TNF-α according to intrana-
sal IL-1RA administration. (A) IL-1β and (B) TNF-α expressions. 
Intranasal administration of IL-1RA more significantly reduced the 
expression of IL-1β and TNF-α mRNA at 6 h after administration 
than the EC group. In each group, 4 rats were assessed at each 
measurement time point. Values are expressed as ratios versus 
the sham controls without MCAO (means [SEM]). *p<0.05, versus 
the EC group by independent 2-tailed t test.
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results show that IL-1RA was already detected in the cortex 
and striatum 1 h after intranasal administration and that the 
IL-1RA level reached the peak at about 1 h after intranasal 
administration in the striatum and 3 h after intranasal adminis-
tration in the cortex. A previous report indicated that a protein 
administered intranasally might take more than 8 h to reach 
brain tissue through endocytosis and axonal transport (Furrer 
et al., 2009). Therefore, our results imposed that after intrana-
sal administration, IL-1RA might be transported to the brain 
tissue largely by the rapid pathway through intercellular clefts. 
In addition, the time to the peak IL-1RA level after intranasal 
administration was faster in the striatum than in the cortex, 
which is probably because IL-1RA is distributed from the ol-
factory bulb and brain stem to the whole brain and that the 
striatum is more adjacent to the olfactory bulb and brain stem 
than the cortex. On the other hand, the peak IL-1RA level in 
the brain tissue of the IP group was only 21-36% of that of 
the IN group, which may be because the penetration of the 
IL-1RA into brain tissue when administered systemically oc-
curred only in the area with damaged BBB. Finally, the neu-
roprotective efficacy against transient focal cerebral ischemia 
in the IN group was superior to that in the IP group, which 
may be because of the difference in the delivery of IL-1RA to 
brain tissue. In a few previous studies, IL-1RA was reported 
to provide significant neuroprotection even when systemically 
administered at a lower dose than that administered in the 
present study (Pradillo et al., 2012; Xia et al., 2014). How-
ever, IL-1RA was administered 1.5-12 h after cerebral isch-
emia induction in these studies, compared to immediately af-
ter ischemia induction in the present study. Because IL-1RA 
has a short half-life in plasma (Kim et al., 1995), the timing of 
administration may have affected the outcome. Furthermore, 
they assessed infarct size and neurological function only at 24 
h after cerebral ischemia. Because the inflammatory process 
after cerebral ischemia evolves for many days (Iadecola and 
Anrather, 2011), the assessment at 24 h after injury may be 
insufficient; thus, neurological outcomes were assessed for 7 
days in this study.
As a response to ischemic brain injury, cytokines are se-
creted from immune cells to trigger an inflammatory response. 
The cytokines that are produced in the early phase after cere-
bral ischemia are reported to be IL-1β and TNF-α (Lambertsen 
et al., 2012). Our results demonstrated that IL-1RA adminis-
tration may reduce the expression of IL-1β and TNF-α in the 
early phase, which might affect overall inflammatory cascade 
after cerebral ischemic injury. In addition, IL-1β is known to 
be implicated in neuroinflammation and worsen cerebral isch-
emic injury by evoking excitotoxicity in neurons and increas-
ing the production of reactive oxygen and proteases in glial 
cells (Galea and Brough, 2013). Therefore, in order to reduce 
the possibility of an inflammatory response, the IL-1 activity in 
neurons and microglia should be blocked. In our results, the 
administered IL-1RA was co-localized with neurons and acti-
vated microglia; thus, IL-1RA administration might block the 
effect of IL-1β on neurons and microglias.
There is a concern that successful application of intranasal 
administration in rodents may not be reproduced in humans 
(Grassin Delyle et al., 2012), which can be the limitation of this 
study. The anatomy of the nasal cavity of rodents quite differs 
from that of humans; the proportion of the olfactory epithelium 
in the nasal cavity is much lower in humans than in rodents 
(3% vs. 50%) (Malerba et al., 2011). The olfactory epithelium 
is innervated by the olfactory nerve and thus is important in 
direct transport to the brain through the extracellular pathway. 
However, direct evidence exists regarding the transport from 
the nose to the brain in human studies (Illum, 2004). Further-
more, various modifications can be made to improve transport 
to the brain, such as changes in drug formulation and perme-
ation enhancers (Illum, 2004; Malerba et al., 2011). Therefore, 
intranasal administration of IL-1RA can be a robust candidate 
method for ischemic stroke management.
In conclusion, intranasal administration of IL-1RA was a 
more efficient route to reach brain parenchyma and showed 
superior efficacy in neuroprotection against transient cerebral 
ischemia in the rats when compared with systemic administra-
tion. Therefore, intranasal delivery of IL-1RA should be inves-
tigated further as a potential therapeutic option for ischemic 
stroke.
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